SCHEMBL1759352

SCHEMBL1759352

CCC(=O)OCc1ccccc1[N+](=O)[O-]

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.55
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
ALDH1A1 P00352 6/20 0.49
HTT P42858 1/20 0.49
TSHR P16473 1/20 0.49
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HPGD P15428 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
MAPK1 P28482 1/20 0.44
POLB P06746 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7458236 0.88 MAOB (0.52) MAOBMEN1KMT2AALDH1A1HTT
SCHEMBL20598466 0.87 MAOB (0.54) MAOBMEN1KMT2AALDH1A1HTT
SCHEMBL1556056 0.87 MAOB (0.54) MAOBMEN1KMT2AALDH1A1HTT
SCHEMBL27809104 0.87 MAPK1 (0.52) MAOBMEN1KMT2AALDH1A1HTT
SCHEMBL27876784 0.86 KMT2A (0.48) MAOBMEN1KMT2AALDH1A1TSHR
SCHEMBL28416934 0.86 ALDH1A1 (0.57) MAOBMEN1KMT2AALDH1A1HTT
SCHEMBL28409395 0.84 MAOB (0.51) MAOBMEN1KMT2AALDH1A1HTT
SCHEMBL5583398 0.84 ALDH1A1 (0.57) MAOBMEN1KMT2AALDH1A1HTT
SCHEMBL6327015 0.84 MAOB (0.51) MAOBMEN1KMT2AALDH1A1HTT
SCHEMBL8643962 0.84 MAOB (0.51) MAOBMEN1KMT2AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2903608-A1 ESTERS OF SHORT CHAINS FATTY ACIDS FOR USE IN THE TREATMENT OF IMMUNOGENIC DISORDERS Proponent Biotech GmbH (CH) 2015-08-12 EP claimed
WO-2014053592-A1 ESTERS OF SHORT CHAINS FATTY ACIDS FOR USE IN THE TREATMENT OF IMMUNOGENIC DISORDERS PROPONENT BIOTECH GMBH (CH) 2014-04-10 WO claimed
CN-107698766-B Branched polyorganosiloxanes and related curable compositions, methods, uses and devices 美国陶氏有机硅公司 2021-02-23 CN disclosed
EP-3004275-B1 IN SITU METHOD FOR FORMING THERMALLY CONDUCTIVE THERMAL RADICAL CURE SILICONE COMPOSITION DOW SILICONES CORP (US) 2020-10-21 EP disclosed
CN-106957594-B Surface treatment composition, method of preparing surface treatment composition, and surface-treated article 美国陶氏有机硅公司 2020-03-03 CN disclosed
EP-2954023-B1 STABLE THERMAL RADICAL CURABLE SILICONE ADHESIVE COMPOSITIONS DOW SILICONES CORP (US) 2019-11-06 EP disclosed
EP-2499209-B1 SURFACE TREATMENT COMPOSITION, PROCESS FOR PRODUCING THE SAME, AND SURFACE-TREATED ARTICLE ESSILOR INT (FR) 2019-08-21 EP disclosed
WO-2019151442-A1 FLUORO (POLY)ETHER GROUP-CONTAINING SILANE COMPOUND ダイキン工業株式会社 2019-08-08 WO disclosed
WO-2019151445-A1 ELECTRONIC DEVICE ダイキン工業株式会社 2019-08-08 WO disclosed
US-10370574-B2 Method for forming thermally conductive thermal radical cure silicone compositions DOW SILICONES CORPORATION (US) 2019-08-06 US disclosed
EP-2954024-B1 CURABLE SILICONE COMPOSITIONS COMPRISING CLUSTERED FUNCTIONAL POLYORGANOSILOXANES AND SILICONE REACTIVE DILUENTS DOW SILICONES CORP (US) 2019-05-15 EP disclosed
US-20130004780-A1 Surface Treatment Composition, Process For Producing The Same, And Surface-Treated Article ESSILOR INTERNATIONAL (FR) 2013-01-03 US disclosed
EP-2499209-A1 SURFACE TREATMENT COMPOSITION, PROCESS FOR PRODUCING THE SAME, AND SURFACE-TREATED ARTICLE Essilor International (Compagnie Générale D'Optique) (FR) 2012-09-19 EP disclosed
CN-102666759-A Surface treatment composition, process for producing the same, and surface-treated article ESSILOR INT 2012-09-12 CN disclosed
WO-2012064989-A1 SURFACE TREATMENT COMPOSITION, METHOD OF PRODUCING THE SURFACE TREATMENT COMPOSITION, AND SURFACE-TREATED ARTICLE DOW CORNING CORPORATION (US) 2012-05-18 WO disclosed
WO-2011060047-A1 SURFACE TREATMENT COMPOSITION, PROCESS FOR PRODUCING THE SAME, AND SURFACE-TREATED ARTICLE ESSILOR INTERNATIONAL (COMPAGNIE GENERAL D'OPTIQUE) (FR) 2011-05-19 WO disclosed
US-7514566-B2 Thiazole compounds and methods of use AMGEN, INC. (US) 2009-04-07 US disclosed
US-20070173506-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2007-07-26 US disclosed
US-6191220-B1 REACTING POLYMER HAVING OLEFINIC OR ACETYLENIC UNSATURATED GROUPS WITH HYDRIDE (HYDROCARBONOXY) SILANE IN PRESENCE OF PLATINUM OR PLATINUM COMPOUND CATALYST AND SILYLATED CARBOXYLIC ACID TO FORM HYDROCARBONOXYSILYL FUNCTIONAL POLYMER DOW CORNING ASIA, LTD. (JP) 2001-02-20 US disclosed
US-5994573-A Method for making triarylamine compounds having hydrocarbonoxysilyl groups DOW CORNING ASIA, LTD. (JP) 1999-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173506-A1 Thiazole compounds and methods of use MTOR, JAK2, PCK2 MAOB 2482/4885MEN1 1825/4885KMT2A 3968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.